Veteran issues in the United States often figure prominently in policy debates and media coverage surrounding psychedelic substances, such as psilocybin mushrooms and ibogaine. This is partially driven by the need to improve access and efficacy of treatments for mental health conditions, especially conditions (such as posttraumatic stress disorder) that are more common among veterans than...
Psychedelic therapies have shown considerable promise in clinical trials, but their effects depend heavily on context—set, setting, therapeutic relationship, and integration—in ways that sit uneasily with health care systems built to finance discrete drugs and billable services. This white paper examines the institutional pathway through which psychedelic therapies may reach patients, from...
An Executive Order signed in April 2026 directed US federal agencies to expedite development and review pathways for psychedelic and psychedelic-adjacent (such as ibogaine) therapies. The FDA issued Commissioner's National Priority Vouchers to psilocybin developers, and cleared the investigational new drug (IND) application for noribogaine hydrochloride for alcohol use disorder. These...
The therapeutic benefits of psychedelics for neuropsychiatric conditions have gathered significant attention in Europe and around the world, with treatments using psilocybin, MDMA, and ketamine as notable examples. However, the mind-altering effects of these substances, and the complexity of their regulatory frameworks, both within and outside of therapeutic use, imply careful clinical...
Abstract Psychedelic drugs can induce intense changes in perception and thought, and some also promote long-lasting adaptations in brain circuits that are being explored for treatment of mood and anxiety disorders. How these compounds differ at the level of intracellular signaling, and how hallucinogenic drugs diverge from related non-hallucinogenic forms, is poorly understood. A central...
Treatment-resistant depression (TRD) is a subset of major depressive disorder (MDD) most commonly defined as failure to respond to 2 or more antidepressant regimens despite adequate dose, duration, and adherence to treatment. The burden of TRD impacts individuals, families, and society, with outcomes such as decreased health-related quality of life and increased health care utilization and...
VérticesSeptember 1, 2026Leticia Almeida Castro, André Luiz Anjos Simões Júnior, Guilherme Gianizeli Corradi Simões et al.
Depression is a multifactorial mental disorder and a leading cause of global disability. A subset of patients does not respond to conventional antidepressants, characterizing treatment-resistant depression (TRD). This study aimed to investigate the therapeutic potential of psilocybin in TRD, focusing on its effects on neuroplasticity. An integrative literature review was conducted using PubMed,...
Background: Epidemiological data on psychedelic use in Italy is limited. In this study, Italian responders in the Global Psychedelic Survey 2025 were subanalyzed to describe patterns of use, motivations, subjective experiences, and health correlates. Methods: Adults (≥21 years) with lifetime psychedelic exposure, residing in or born in Italy or San Marino, were surveyed in a web-based,...
Psychedelic-assisted therapy has emerged as a prominent area for psychiatric investigation particularly with regards to treatment-resistant depression and Post Traumatic Stress Disorder (PTSD). The purpose of this narrative review was to outline the current body of research regarding psychedelic and psychedelic-like compounds in these two psychiatric conditions highlighting psilocybin-assisted...
Nursing Edição BrasileiraAugust 27, 2026Ana Júlia Costa Matias Gomes, Jéssica Camilo Ramos Rodrigues, Valber Pinheiro Padilha Filho
Os psicodélicos clássicos, como a psilocibina, o LSD e a DMT, têm despertado crescente interesse na psiquiatria moderna devido ao seu potencial terapêutico em transtornos resistentes ao tratamento. O mecanismo de ação primário dessas substâncias envolve o agonismo dos receptores de serotonina 5-HT2A, localizados principalmente no córtex pré-frontal. Esta revisão sistemática analisou como a...